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Abstract 
Acute pancreatitis (AP) is a common and devastating inflammatory 
condition of the pancreas that is considered to be a paradigm of sterile 
inflammation leading to systemic multiple organ dysfunction syndrome (MODS) 
and death1,2 Acute mortality from AP-MODS exceeds 20%3 and for those who 
survive the initial episode, their lifespan is typically shorter than the general 
population4. There are no specific therapies available that protect individuals 
against AP-MODS. Here, we show that kynurenine-3-monooxygenase (KMO), a 
key enzyme of tryptophan metabolism5, is central to the pathogenesis of AP-
MODS. We created a mouse strain deficient for Kmo with a robust biochemical 
phenotype that protected against extrapancreatic tissue injury to lung, kidney 
and liver in experimental AP-MODS. A medicinal chemistry strategy based on 
modifications of the kynurenine substrate led to the discovery of GSK180 as a 
potent and specific inhibitor of KMO. The binding mode of the inhibitor in the 
active site was confirmed by X-ray co-crystallography at 3.2 Å resolution. 
Treatment with GSK180 resulted in rapid changes in levels of kynurenine 
pathway metabolites in vivo and afforded therapeutic protection against AP-
MODS in a rat model of AP. Our findings establish KMO inhibition as a novel 
therapeutic strategy in the treatment of AP-MODS and open up a new area for 
drug discovery in critical illness. 
Systemic tryptophan metabolism in mammals occurs primarily via the 
kynurenine pathway (Fig. 1a)5. Tryptophan metabolites contribute to acute lung 
injury in rats with AP6,  while the tryptophan metabolite kynurenine is elevated 
in blood in humans with severe AP6. Sitting at a critical fork in the pathway, 
kynurenine–3–monooxygenase (KMO) metabolizes kynurenine to 3–
hydroxykynurenine, which increases oxidative stress9, induces apoptosis10 and is 
injurious to several cell types7. Inhibition of KMO should reduce 3–
hydroxykynurenine production which may therefore provide an efficacious 
strategy to prevent or reduce the severity of extrapancreatic organ injury in AP. 
 To explore the role of KMO in disease processes we created a mouse 
strain that lacks KMO activity constitutively in all tissues (Supplementary Fig. 
1a). Anatomical mapping of tissue Kmo mRNA expression in wild-type C57BL6 
mice showed high levels of Kmo expression in liver and kidney and moderate 
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Kmo mRNA expression in organs containing secondary lymphoid tissue, 
specifically lung, spleen, mesenteric lymph node, thymus and peripheral lymph 
nodes (Supplementary Fig. 1b).   Mice homozygous for the Kmo knockout-first 
tm1a allele (from hereon referred to as Kmonull mice) were shown to have no 
detectable messenger RNA for Kmo in any tissues. Liver homogenates from 
Kmonull mice lacked the ability to convert kynurenine to 3–hydroxykynurenine, 
but this activity was restored to wild type levels in mice where the inserted stop 
signal had been removed (KmoFRT-deleted mice) showing that the defect resulted 
from the specific engineered mutation (Supplementary Fig. 1c). 
 We explored the pathways of kynurenine metabolism by measuring 
upstream, downstream and alternative pathway metabolites (Fig. 1b–g). 
Compared to KmoFRT-deleted  mice, Kmonull mice show equivalent steady state 
tryptophan concentrations and profound depletion of 3–hydroxykynurenine 
([tryptophan]plasma in KmoFRT-deleted vs. Kmonull mice: 28 ± 1 μM vs. 28 ± 1 μM, P = 
0.843 (t-test); [3–hydroxykynurenine]plasma in KmoFRT-deleted vs. Kmonull mice: 32 ± 
3 nM vs BLQ, P < 0.001 (t-test); n = 5 per group). Kmonull mice have a 19-fold 
backlog of kynurenine upstream, indicating that KMO is normally the 
predominant pathway for metabolism of kynurenine ([kynurenine]plasma in 
KmoFRT-deleted vs. Kmonull mice: 0.6 ± 0.1 μM vs. 11.0 ± 1.0 μM, P < 0.001 (t-test), n = 
5 per group). There is preferential diversion of kynurenine metabolism to 
kynurenic acid in the Kmonull mice, with steady-state levels 81-fold higher than in 
KmoFRT-deleted mice ([kynurenic acid]plasma in KmoFRT-deleted vs. Kmonull mice: 0.1 ± 0.0 
μM vs. 11.0 ± 1.2 μM; P < 0.001 (t-test), n = 5 per group). Metabolism of 
kynurenine can also bypass KMO and be converted by kynureninase to 
anthranilic acid and subsequently to 3–hydroxyanthranilic acid by non-specific 
hydroxylase activity5, but this pathway was less active with levels of anthranilic 
acid only 4-fold higher in Kmonull mice ([anthranilic acid]plasma in KmoFRT-deleted vs. 
Kmonull mice: 0.3 ± 0.1 μM vs. 1.0 ± 0.1 μM; P < 0.001 (t-test), n = 5 per group). 
Kmonull mice have reduced serum 3–hydroxyanthranilic acid concentrations in 
the steady state, although the reduction is less than observed for 3–
hydroxykynurenine ([3–hydroxyanthranilic acid]plasma in KmoFRT-deleted vs. Kmonull 
mice: 2.0 ± 0.3 μM vs. 1.1 ± 0.2 μM; P=0.034 (t-test), n = 5 per group). These data 
support the notion that under normal conditions 3–hydroxyanthranilic acid is 
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produced primarily via 3–hydroxykynurenine rather than via anthranilic acid, 
but suggests that the pathway to bypass KMO can function to some degree when 
KMO is absent. Together, these data show that KMO is the key gatekeeper 
enzyme that determines the metabolic fate of kynurenine. 
 We next tested whether the absence of KMO activity affected 
extrapancreatic organ injury in experimental AP induced by injection of 
taurocholate into the biliopancreatic duct at laparotomy. Pancreata from sham-
operated mice showed normal architecture and no signs of inflammation while 
those from AP mice showed evidence of necrosis, interlobular edema and a 
pronounced inflammatory cell infiltrate (Supplementary Fig 2a,b). No 
difference in pancreatic injury was noted in Kmonull compared to Kmowt control 
mice (Fig. 2a) (composite histological score Kmowt sham vs. AP: 0.0 ± 0.0 vs.  7.1 
± 0.4; Kmonull sham vs. AP: 0.0 ± 0.0 vs. 7.3 ± 0.7; P < 0.001 one-way ANOVA 
across all groups, post hoc Student–Neumann–Keuls (S–N–K) threshold P < 0.05 
significant for sham vs. AP in both mouse strains, Kmonull AP vs. Kmowt AP not 
significant (n.s.); n =  6 or 7 per group). The majority of infiltrating inflammatory 
cells were positive for the neutrophil marker myeloperoxidase (MPO) by 
immunohistochemistry (Supplementary Fig. 2b) and there was no significant 
difference in the number of infiltrating neutrophils in the pancreas between 
Kmonull compared to Kmowt mice with AP (Supplementary Fig. 2c). There was 
no significant infiltrate of cells positive for the mouse monocyte marker F4/80 
(Supplementary Fig. 2d). Serum amylase concentration was substantially 
elevated in AP in both strains but less so in Kmonull compared to Kmowt mice 
(Supplementary Fig. 2e).  
IL-6 trans-signalling has been reported to contribute to extrapancreatic 
organ injury in experimental mouse AP8 and indeed serum IL-6 concentrations 
were elevated in AP compared to sham mice in both Kmowt and Kmonull mice 
(Supplementary Fig. 3a). There was no statistically significant rise in serum IL-
10 in AP in either Kmowt or Kmonull mice (Supplementary Fig. 3b). Kynurenine 
pathway metabolite levels confirmed the biochemical phenotype seen in 
unstressed mice and showed a small depletion of tryptophan as a result of AP 
(Supplementary Fig. 3c–f). 
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 The lung is the extrapancreatic organ system most commonly affected in 
humans with AP.  Experimental AP in Kmowt mice generated histological changes 
consistent with moderate acute respiratory distress syndrome, specifically 
thickening of the alveolar walls characterized by congestion of alveolar 
capillaries, interstitial edema and leukocyte infiltrates and exudation of 
proteinaceous edema fluid into alveolar spaces. This pathology was still 
detectable in Kmonull mice with AP to some degree, although it was much less 
marked (Fig. 2b,c and Supplementary Fig. 4a–d). MPO-positive infiltrating 
neutrophils in lung were more numerous during AP in Kmowt compared to 
Kmonull mice (Supplementary Fig. 4e). Experimental AP increased the number 
of apoptotic cells in both strains, significantly so in Kmowt mice (Fig. 2d) (Kmowt 
sham vs. AP: 3 ± 1 vs. 21 ± 9 TUNEL-positive cells/106 pixels; Kmonull sham vs. 
AP: 2 ± 0 vs. 6 ± 1 TUNEL-positive cells/106 pixels; P = 0.033 one-way ANOVA 
across all groups, post hoc S-N-K threshold P < 0.05 significant for Kmowt sham 
vs. AP and Kmowt AP vs. Kmonull AP; Kmonull sham vs. AP n.s.; n = 6 or 7 per group).  
Acute kidney injury (AKI) frequently follows lung injury during AP-MODS 
in a cumulative manner9. Experimental AP led to a dramatic increase in kidney 
cell apoptosis which was markedly lower in Kmonull mice vs. Kmowt controls (Fig. 
2e) (Kmowt sham vs. AP: 2 ± 0 vs. 18 ± 5 TUNEL-positive cells/106 pixels; Kmonull 
sham vs. AP: 1 ± 0 vs. 6 ± 2 TUNEL-positive cells/106 pixels; P=0.001 one-way 
ANOVA across all groups, post hoc S-N-K threshold P < 0.05 significant for Kmowt 
sham vs. AP and Kmowt AP vs. Kmonull AP; Kmonull sham vs. AP n.s.; n = 6 or 7 per 
group). There was no evidence of histological damage (Supplementary Fig. 5a–
d)  or inflammatory infiltrate (Supplementary Fig. 5e,f), and no significant 
functional impairment as creatinine levels were not changed (Fig. 2f) 
([creatinine]serum Kmowt sham vs. AP: 16 ± 5 vs. 23 ± 5 mmol/L; Kmonull sham vs. 
AP: 5 ± 1 vs. 9 ± 2 mmol/L; P = 0.019 one-way ANOVA across all groups, post hoc 
S-N-K threshold P < 0.05 not significant for Kmowt sham vs. AP, Kmowt AP vs. 
Kmonull AP or Kmonull sham vs. AP; n = 5 to 7 per group). The baseline serum 
creatinine in Kmonull mice appeared lower than in Kmowt mice, although this was 
not statistically significant.  
Experimental AP induced a biochemical liver injury in Kmowt and Kmonull 
mice, but when KMO activity was absent, the magnitude of the rise in alanine 
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aminotransferase (ALT), a marker of hepatocyte necrosis, was significantly 
reduced (Fig. 2g) ([ALT]plasma Kmowt sham vs. AP: 49 ± 14 vs. 672 ± 68 mmol/L; 
Kmonull sham vs. AP: 38 ± 4 vs. 352 ± 36 mmol/L; P < 0.001 one-way ANOVA 
across all groups, post hoc S-N-K threshold P < 0.05 significant for sham vs. AP in 
both strains and Kmowt AP vs. Kmonull AP; n = 5 to 7 per group) . 
In critically ill individuals, the intravenous route of drug administration is 
preferred as it provides both ease of administration and control. Several small 
molecule KMO inhibitors have been reported in the literature for the potential 
treatment of Huntington’s disease10 but all lack the physicochemical properties 
required for the clinical development of an intravenous drug. Previous studies 
suggested that both the carboxylic acid and the carbonyl group present in 
kynurenine were required for activity11. Therefore, a series of propanoic acid 
heterocycles were prepared which contained H-bond accepting groups to mimic 
the role of the carbonyl functionality, leading to the discovery of the 
oxazolidinone GSK180 (Fig. 3a). 
 GSK180 has a half maximum inhibitory concentration (IC50) of 
approximately 6 nM (mean ± SD pIC50 8.2 ± 0.17 (n = 103)) in a human KMO 
biochemical assay using human KMO expressed as a GST-fusion protein in a 
baculovirus expression system12 (Fig. 3b). The observed potency of GSK180 
decreased as the concentration of kynurenine was increased showing that the 
inhibition by GSK180 is competitive with the kynurenine substrate 
(Supplementary Fig. 6a). GSK180 showed negligible activity against other 
enzymes on the tryptophan pathway (Supplementary Table 1), against a panel 
of over 50 unrelated proteins (Supplementary Table 2) and against an 
additional series of acidergic proteins (Supplementary Table 3). 
Human KMO was cloned and stably expressed in HEK293 cells where it 
conferred the ability to convert kynurenine to 3–hydroxykynurenine with an 
apparent Km for kynurenine of 78 ± 12 µM (Supplementary Fig. 6b). GSK180 
has a mean half maximum inhibitory concentration (IC50) of 2.0µM in this cell-
based assay (mean pIC50 5.7 ± 0.15 (n = 4)) (Fig. 3b). Primary human 
hepatocytes express endogenous KMO activity, and GSK180 inhibited this 
activity with comparable potency (IC50 = 2.6 µM) (Fig. 3b). As the 2-amino-2-
(hydroxymethylpropane-1,3-diol) salt (Tris salt), GSK180 has high aqueous 
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solubility of 24 mg/mL in saline and high microsomal metabolic stability across 
species (clearance <0.5 ml/min/g in rat, dog, human tissue) (data not shown). 
Following bolus intravenous injection into rats, GSK180 showed a low volume of 
distribution and low clearance (Vdss 0.14 L/kg, t1/2 3 h, Clp 0.45 ml/min/kg at 27 
mg/kg i.v. dose) (Fig. 3c). GSK180 is thus a low molecular weight (MW 276), 
highly selective KMO inhibitor with properties suitable for i.v. administration. 
 The structure of human KMO remains elusive, but that of the yeast 
orthologue has recently been reported13. We utilized KMO from P. fluorescens 
where all the residues surrounding the catalytic site are conserved compared to 
human KMO, with the exception of His320, which is a phenylalanine in the 
human protein. Despite this level of conservation, GSK180 demonstrated 
significantly lower potency against P. fluorescens compared to the human 
construct. (IC50 = 500 nM vs. 6 nM, respectively). Nonetheless a 3.2 Å resolution 
co-crystal structure of GSK180 bound to P. fluorescens KMO was solved and 
revealed significant interactions within the catalytic site (Fig. 3d). The 
carboxylate forms a salt bridge with Arg84 and forms hydrogen bonds with the 
side chains of Tyr98 and Asn369. The oxazolidinone carbonyl forms a hydrogen 
bond with the side chain of the C-terminal domain residue Tyr404 and the 5-
chlorine atom forms a π-interaction with Phe238. 
Rat Kmo was expressed in HEK cells in a manner exactly analogous to the 
human enzyme described above where the activity showed an apparent Km for 
kynurenine of 258 ± 121 µM (Supplementary Fig. 6c). GSK180 inhibited rat 
KMO slightly less potently than the human enzyme, giving an IC50 of 7 µM (mean 
pIC50 5.2 ± 0.09 (n = 5)) (Fig. 3b). When dosed to rats as an i.v. bolus at 27 
mg/kg, the initial concentration of GSK180 was nearly 600 µM in blood (Fig. 3c). 
GSK180 is excluded from rat erythrocytes (blood:plasma ratio of 0.46) and is 
moderately bound to rat plasma proteins (free fraction 7.7% at 1 mM, n = 2), 
meaning that the peak free drug levels in plasma (92 µM) are >12 fold above the 
IC50 in cells. Indeed, treatment with GSK180 resulted in a rapid increase in 
circulating levels of both kynurenine and kynurenic acid that returned to 
baseline as the drug levels dropped (Fig. 3c). Levels of 3–hydroxykynurenine in 
this experiment were too low to be accurately measured. The changes observed 
in kynurenine are exactly as expected, but the change in kynurenic acid is 
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curious as the peak occurs prior to the peak of kynurenine suggesting that the 
increase seen is not simply a result of the increase in availability of substrate.  
To explore whether the changes in metabolites observed in the presence 
of drug were due to inhibition of KMO alone or mediated by another mechanism, 
GSK180 was dosed to Kmowt and Kmonull mice as a single bolus injection at 30 
mg/kg which delivered plasma drug levels one hour post dose of 263 ± 98 µM 
and 351 ± 87 µM respectively. Administration of GSK180 resulted in an increase 
in kynurenine in the Kmowt mice, but no change was seen in the Kmonull mice 
confirming that this increase results from inhibition of KMO (Supplementary 
Fig. 6d). Curiously GSK180 caused a significant reduction in circulating 
tryptophan levels in both Kmowt and Kmonull mice, suggesting that the compound 
was having an additional effect unrelated to KMO inhibition. Moreover a clear 
increase in kynurenic acid was also observed in the Kmonull mice, suggesting that 
the changes observed in kynurenic acid in the presence of compound result both 
from metabolic diversion as a result of KMO inhibition and an effect on 
kynurenic acid metabolism that is not mediated by KMO (Supplementary Fig. 
6d).  
On further investigation we confirmed that a similar drop in circulating 
tryptophan was seen in rats, and moreover that it occurred immediately after 
compound administration and was stable for several hours, recovering slowly as 
the plasma level of the compound dropped below 300 µM (Supplementary Fig. 
6e). Tryptophan is the only amino acid that is bound to plasma proteins and high 
concentrations of drugs such as salicylate have been shown to compete with this 
binding14. Indeed, GSK180 showed a concentration dependent displacement of 
tryptophan from plasma proteins in the range equivalent to the exposures 
observed in this study (Supplementary Table 4). However the free tryptophan 
level remains constant (40 µM (22% of 180 µM) in control and 42 µM (60% of 70 
µM) directly after compound administration) suggesting that the displaced 
tryptophan is distributing rapidly into tissues.  
Despite the confounding effects of GSK180 on the pathway outside of 
KMO inhibition, the dynamics of the change in kynurenine seen following 
inhibition demonstrate that even under resting conditions flux through KMO is 
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rapid and is thus consistent with a role for tryptophan metabolism via KMO 
being an important and early contributory mechanism in AP-MODS. 
We next tested the efficacy of GSK180 in protecting against AP-MODS in a 
well-validated rat model of AP that generates secondary organ dysfunction 
within 6 hours of the initial insult6. GSK180 was given in a therapeutic setting 1 
hour after the induction of AP as an i.v. bolus of 24 mg/kg followed by an i.v. 
infusion of 5.5 mg/kg/hour. This delivered stable plasma drug levels of 
approximately 600 µM throughout the experiment which resulted in biochemical 
changes consistent with those seen in the Kmonull mouse and in unchallenged 
animals, namely increased plasma kynurenine and kynurenic acid and decreased 
plasma tryptophan and 3–hydroxykynurenine (Supplementary Fig. 7a).  
The experimental model induced pancreatic acinar cell necrosis, edema 
and an inflammatory cell infiltrate (Supplementary Fig. 7b–d), with elevated 
serum amylase at 6 hours (Supplementary Fig. 7e). The severity of the 
histological injury and the magnitude of the serum amylase rise were equivalent 
in both AP and GSK180-treated groups (Fig. 4a and Supplementary Fig. 7e). 
The intense inflammatory cell infiltrate in AP consisted of MPO-positive 
neutrophils and ED1-positive monocytes, which were present to the same extent 
in pancreas tissue in AP + GSK180-treated rats (Supplementary Fig. 7d,f).  
AP-MODS was associated with an acute rise in ALT, indicating hepatocyte 
injury, which was small in magnitude and equivalent in AP compared to AP + 
GSK180 treated rats; both groups of rats with AP became relatively 
hypoglycaemic compared to sham-operated controls, while serum albumin 
concentrations were only marginally affected (Supplementary Fig. 7g–i). An 
elevation in systemic IL-6 concentrations was seen in experimental AP, which 
was of lesser magnitude in rats with AP treated with GSK180 (Supplementary 
Fig. 7j). Interestingly, IL-10 concentrations were marginally but statistically 
significantly higher in AP rats and higher again in rats with AP treated with 
GSK180 (Supplementary Fig. 7k) 
Acute lung injury (ALI) with features consistent with acute respiratory 
distress syndrome (ARDS) was observed on histological sections of lung tissue 
from rats with AP (Fig. 4b and Supplementary Fig. 8a–c).  They also showed an 
increase in neutrophilic inflammation (Fig. 4c,d), lung protein leak (measured as 
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an increase in total protein concentration in bronchoalveolar fluid) (Fig. 4e), an 
increase in the circulating serum concentration of Krebs von den Lungen 6 (KL-
6) (a type II pneumocyte MUC1-like glycoprotein and marker of incipient ALI in 
humans15,16) (Fig. 4f), and increased apoptosis (Fig. 4g and Supplementary Fig. 
8d). All these features of ALI were essentially prevented by treatment with 
GSK180 ([total protein]BAL6h in sham vs. AP vs. AP + GSK180 rats, 245 ± 18 mg/L 
vs. 332 ± 18 mg/L vs. 142 ± 6 mg/L, P < 0.001 one-way ANOVA across all groups, 
post hoc S-N-K threshold P < 0.05 significant between all groups, n = 7 to 8 rats 
per group; [KL-6]serum6h in sham vs. AP vs. AP + GSK180 rats, 12 ± 1 ng/mL vs. 39 
± 3 ng/mL vs. 16 ± 2 ng/mL, P < 0.001 one-way ANOVA across all groups, post 
hoc S-N-K threshold P < 0.05 significant for sham vs. AP and AP vs. AP + GSK180, 
sham vs. AP + GSK180 n.s.; n = 7 to 8 per group; sham vs. AP vs. AP + GSK180 
rats: 0.9 ± 0.2 vs. 3.3 ± 0.7 vs. 1.7 ± 0.4 TUNEL-positive cells/106 pixels; P=0.004 
one-way ANOVA across all groups, post hoc S-N-K threshold P < 0.05 significant 
for sham vs. AP and AP vs. AP + GSK180, sham vs. AP + GSK180 n.s.; n = 7 to 8 
rats per group (sham vs. AP vs. AP + GSK180 rats: 97 ± 20 vs. 180 ± 21 vs. 105 ± 
70 MPO-positive cells/106 pixels; P=0.011 one-way ANOVA across all groups, 
post hoc S-N-K threshold P < 0.05 significant for sham vs. AP and AP vs. AP + 
GSK180, sham vs. AP + GSK180 n.s.; n = 7 to 8 rats per group). Interestingly, an 
infiltrating population of ED1-positive cells was present in lung tissue in both AP 
groups and significantly elevated in rats with AP treated with GSK180 
(Supplementary Fig. 8e). 
Experimentally-induced AP in rats resulted in a significant increase in 
TUNEL-positive renal tubular cells per unit area of tissue in the outer medullary 
stripe (the key anatomical region for acute tubular injury17) (Fig. 4h) (sham vs. 
AP vs. AP + GSK180 rats 1.3 ± 0.5 vs. 7.4 ± 1.3 vs. 2.1 ± 0.3 TUNEL-positive 
cells/106 pixels; P < 0.001 one-way ANOVA across all groups, post hoc S-N-K 
threshold P < 0.05 significant for sham vs. AP and AP vs. AP + GSK180, sham vs. 
AP + GSK180 n.s.; n = 7 to 8 rats per group). There was no evidence of 
histological damage (Supplementary Fig. 9a–c) or inflammatory infiltrate 
(Supplementary Fig. 9d) but in the rat model of AP we observed a significant 
loss of renal function as evidenced by elevated serum creatinine and urea at 6 
hours after AP induction (Fig. 4i,j). Therapeutic administration of GSK180 in AP 
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protected against all aspects of this kidney injury ([creatinine]serum6h in sham vs. 
AP vs. AP + GSK180 rats, 23 ± 2 mmol/L vs. 52 ± 8 mmol/L vs. 29 ± 5 mmol/L, 
P=0.007 one-way ANOVA across all groups, post hoc S-N-K threshold P < 0.05 
significant for sham vs. AP and AP vs. AP + GSK180, sham vs. AP + GSK180 n.s.; 
[urea]serum6h in sham vs. AP vs. AP + GSK180 rats, 8.2 ± 0.5 mmol/L vs. 13.4 ± 0.9 
mmol/L vs. 10.7 ± 0.8 mmol/L, P < 0.001 one-way ANOVA across all groups, post 
hoc S-N-K threshold P < 0.05 significant between all groups; n = 7 to 8 rats per 
group). A modest but statistically significant increase in ED1-positive cell counts 
in the kidneys of rats with AP treated with GSK180 was observed 
(Supplementary Fig. 9e).  
The development of MODS (and particularly ARDS) is a key determinant of 
outcome in critically ill individuals regardless of the initiating event4. AP serves 
as a paradigm for sterile systemic inflammation, and this work builds on a 
rapidly expanding body of work uncovering the potential role of the kynurenine 
pathway in several inflammatory and degenerative disease states, and is the first 
to demonstrate therapeutic efficacy of KMO inhibition to protect against MODS.  
Increased tryptophan metabolism through the kynurenine pathway has 
been detected in systemic inflammation in humans during AP6, trauma18,19, 
coronary artery bypass surgery20, sepsis21, and chronic renal failure22. Oxidative 
stress and apoptotic cell death mediated by 3–hydroxykynurenine have been 
proposed as drivers of disease23,22. How 3–hydroxykynurenine results in tissue 
injury in AP is yet to be fully elucidated, but inference can be made from related 
experiments. In primary cultured neurons, 3–hydroxykynurenine causes cell 
death by apoptosis by producing reactive oxygen species including superoxide 
radicals and hydrogen peroxide (H2O2)24,25, which can be counteracted by anti-
oxidants26 or blockade of intracellular peroxidase activity24. Furthermore, the 
oxidation product of 3–hydroxykynurenine itself, a short-lived quinone-imine, is 
highly reactive with the thiol and amine groups of proteins27.  
 KMO inhibition increases plasma concentrations of kynurenic acid, which 
may be potentially protective and also harmful in the context of AP. Kynurenic 
acid activates the G-protein coupled receptor, GP35, and in doing so inhibits LPS-
induced TNF release from human peripheral blood mononuclear cells28. In mice 
given a near-lethal dose of LPS, kynurenic acid administration prevents TNFα 
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release and reduces lethality29. kynurenic acid elevation during KMO blockade 
may also therefore contribute to the benefit seen in Kmonull mice with AP and 
GSK180-treated rats with AP by exerting an anti-inflammatory effect on innate 
immune cells. Kynurenic acid elevates the seizure threshold of mice and rats 
given intracerebral quinolinic acid by potent antagonism at the glycine allosteric 
site of the NMDA receptor complex, and therefore a KMO inhibitor may be 
sedative. 
The mechanisms leading to increased kynurenine pathway metabolites 
during sterile systemic inflammation are complex. Certainly it is clear that 
increased kynurenine substrate is made available through increased IDO activity 
in extra-hepatic tissues30. IDO is profoundly upregulated by bacterial 
lipopolysaccharide and pro-inflammatory cytokines, in particular IFNγ30. 
Furthermore, inflammation-induced tryptophan–2,3–dioxygenase activity 
resulting in increased levels of kynurenine regulates the induction of tolerance to 
lipopolysaccharide and is dependent on IDO1 activity31. These orthodox 
inflammatory signals also upregulate KMO activity in human monocytes32 and 
monocyte-derived macrophages33. Human monocytes show increased gene 
expression of IDO1, KMO and QPRT (quinolinate phosphoribosyltransferase, a 
gene encoding an enzyme downstream in the kynurenine pathway) when 
incubated with IFNγ, and KMO expression correlates with kynurenine pathway 
activation measured by the tryptophan:kynurenine ratio34. Interleukin-1β  (IL-
1β) is also reported to drive upregulated KMO mRNA expression35. Interestingly, 
the induction of IDO expression in vitro in response to the toll-like receptor 
agonists LPS and CpG has been shown to be dependent on the presence of a 
functioning aryl hydrocarbon receptor (AhR) complex36,37. Furthermore, 
kynurenine is now regarded as a potent AhR ligand and together this complex is 
a key mechanistic contributor to endotoxin tolerance31,38. Exogenous kynurenine 
added in co-culture of dendritic cells with T-lymphocytes rescues a type 1 T-
regulatory phenotype, limits Th17 cell induction and reduces Th17 cytokine 
release in an AhR-null system when compared to AhR-competent co-cultures36. 
This is congruent with the observation that the presence of kynurenine during 
CD3/CD28 antibody-induced T-cell proliferation decreases overall 
proliferation38 and increases the proportion of FoxP3+ T-regulatory cells 
 13
generated37. It is possible, although yet to be explicitly defined, that these 
adaptive immune-cell mediated mechanisms may contribute to the efficacy of 
KMO inhibition shown in our experiments. Furthermore, the increase in 
kynurenine as a consequence of KMO inhibition may also contribute to free-
radical scavenging. Experimentally, addition of kynurenine scavenges hydrogen 
peroxide and, to a lesser extent, superoxide radical, and has a concentration-
dependent inhibitory effect on the production of reactive oxygen species by 
activated neutrophils, without directly affecting NADPH oxidase function or 
phagocytosis39. 
In Kmonull mice, fecundity, fertility and longevity up to 2 years of age are not 
affected, from which we can infer that prolonged KMO blockade with consequent 
chronic exposure to significantly elevated concentrations of kynurenic acid and 
kynurenine is well tolerated, at least in adapted mice. Independently, a second 
Kmonull mouse strain has been generated by others40, which has an identical 
biochemical phenotype to the Kmonull mouse strain generated by iKOMP and us. 
Together, the clear biochemical phenotypic changes in these two independently 
generated Kmonull mice strains demonstrate unequivocally that KMO activity 
defines the metabolic fate of kynurenine.  
GSK180 is a potent inhibitor of isolated KMO, but is less potent in the 
cellular context. The passive permeability of GSK180 across an artificial 
membrane was measured and found to be extremely low (< 3 x 10-6 cms-1, n = 3) 
and measurement of drug concentration confirms that the intracellular level is 
more than 30 times lower than the extracellular concentration. It therefore 
seems reasonable to conclude that the lower potency observed in the cell-based 
assay is based on poor access of the compound into the intracellular 
compartment, necessitating higher drug levels to show pharmacodynamic 
activity. This leads to the unwanted (non-KMO mediated) effects on tryptophan 
and kynurenic acid but, used carefully, GSK180 remains a useful tool to probe the 
therapeutic potential of KMO inhibition. Improving cell potency will be a key 
component of the search for a clinical candidate. 
AP-MODS is an early event in the overall disease course of AP, occurring in 
the first few hours to days after the onset of symptoms3,9. If we are to rationalize 
KMO activity as a key contributor to AP-MODS, tryptophan and kynurenine 
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metabolism must be rapid and occur within the expected timeframe of onset of 
AP-MODS. The rate of change in metabolite levels following administration of 
GSK180 strongly support this, and provide convincing evidence that kynurenine 
metabolism occurs within a disease-relevant time course and that tryptophan is 
continuously metabolized and replenished to the plasma compartment on a large 
scale. Importantly, this rate of metabolic flux is well within the proposed 
timescale of tryptophan metabolism via KMO as an important and early 
contributory mechanism in AP-MODS. In addition, because KMO inhibition 
protects against extrapancreatic organ injury without a need to diminish the 
severity of the initiating pancreatic tissue damage, the clinical applicability is 
enhanced.  
In conclusion, our experiments demonstrate a novel contributory 
metabolic mechanism of remote organ injury triggered by sterile initiators of 
systemic inflammation. Moreover, we have also shown that the metabolic target, 
KMO, is susceptible to therapeutic blockade. Together, these data strongly 
support a therapeutic role for KMO inhibitors in critical illness. Our findings 
therefore establish KMO inhibition as a novel therapeutic strategy in AP-MODS 
and possibly other severe acute systemic inflammation. 
Accession codes 
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Figure legends 
 
Figure 1. The kynurenine pathway of tryptophan metabolism (a) Diagram of the 
kynurenine pathway. (b–g) Kmonull mouse steady state kynurenine metabolite 
serum concentrations. Graphs show individual data with horizontal lines 
showing mean ± s.e.m. BLQ = below limit of quantitation. Dashed line (---) shows 
LQ for 3–hydroxykynurenine. *P < 0.05 by independent samples t-test (two-
sided), n = 5 mice per group. All mice were male. For panel d, values that were 
BLQ were assigned the LQ value to allow statistical analysis. 
 
Figure 2. Kmonull mice are protected against lung, liver and kidney injury during 
experimental AP. (a) Composite histological pancreas injury score. (b) 
Representative lung tissue photomicrographs (haematoxylin and eosin stain) 
from Kmowt mice with AP (n = 7) show lung injury manifested as thickening of 
alveolar walls with vascular congestion (black arrow), interstitial oedema (white 
arrow) and inflammatory cell infiltrates (blue arrow) compared to lung tissue 
from sham control Kmowt mice (n = 7) and sham control Kmonull mice (n = 6). This 
pathology is less marked in lung tissue from Kmonull mice with AP (n = 7). Scale 
bar, 300 µm. (c) Lung neutrophil infiltration in response to AP. Representative 
immunohistochemistry images show neutrophil infiltration (MPO+ cells, brown-
stained, white arrow) into lung tissue from AP mice but not sham control mice. 
Scale bar, 300 µm. Group sizes as for panel b (d) Apoptotic TUNEL+ cell counts in 
lung tissue. (e) Apoptotic TUNEL+ cell counts in kidney tissue. (f) Serum alanine 
aminotransferase (ALT) concentrations. (g) Serum creatinine concentrations. All 
panels: Data are plotted for individual mice with horizontal lines showing mean 
± s.e.m. *P < 0.05, **P < 0.01 and ***P < 0.001 by ANOVA with post hoc Student-
Newman-Keuls homogeneous subset analysis (subset for α = 0.05); N.S. = not 
significant. For panels f and g, for Kmonull mice with AP, the group size is (n = 5) 
due to blood sampling failure in 2 mice. 
 
Figure 3. Discovery of the KMO inhibitor GSK180. (a) Kynurenine cyclization 
strategy that led to the discovery of GSK180. (b) Indicative dose-response 
inhibition plots of GSK180 vs. human KMO expressed in insect cell lysates, 
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human and rat KMO expressed in intact HEK293 cells and human primary 
hepatocytes. (c) Pharmacokinetic/pharmacodynamic profile of GSK180 in rat 
administered as an i.v. bolus. Plasma levels of drug and concentrations of 
kynurenine and kynurenic acid are shown. Data are mean ± s.d. of n = 3 rats. (d) 
Crystal structure of KMO in complex with the inhibitor. Enzyme residues (grey) 
surrounding the bound inhibitor (cyan) are shown in stick representation, with 
hydrogen bonds shown as dashed lines (magenta). Heteroatoms are colored 
according to atom type: nitrogen (blue), oxygen (red), sulphur (yellow) and 
chlorine (green). 
 
Figure 4. Therapeutic administration of GSK180 protects against lung, liver and 
kidney injury during experimental AP in rats. (a) Composite histological 
pancreas injury score. (b) Representative photomicrographs of lung tissue 
stained with haematoxylin and eosin shows secondary lung injury in untreated 
rats with AP (n = 7) compared to sham control rats (n = 8) and GSK180-treated 
rats with AP (n = 7) manifested as alveolar wall thickening (white arrow), 
inflammatory cell infiltration (black arrow) and vascular congestion (blue 
arrow). Scale bar, 300 µm. (c) Lung neutrophil infiltration in experimental AP. 
Representative immunohistochemistry images show neutrophil infiltration 
(MPO+ cells, brown-stained, white arrow) into lung tissue from AP rats (n = 7)  
but not sham control rats (n = 8). GSK180 treated rats (n = 7) have reduced lung 
neutrophil infiltration. Scale bar, 300 µm. (d) Enumeration of MPO+ cells/106 
pixels in lung tissue. (e) Lung bronchoalveolar lavage protein concentration. (f) 
Serum concentrations of the glycoprotein lung injury biomarker Krebs von den 
Lungen-6 (KL-6) (g) Enumeration of TUNEL+ cells/106 pixels in lung tissue (h) 
Enumeration of TUNEL+ cells/106 pixels in kidney tissue. (i) Serum creatinine 
concentrations. (j) Serum urea concentrations. All panels: Group sizes were: 
sham n = 8, AP n = 7 and AP + GSK180 n = 7 rats. Unless otherwise stated, data 
are plotted for individual rats with horizontal lines show mean ± s.e.m. *P < 0.05, 
**P < 0.01 and ***P < 0.001 by ANOVA with post hoc Student-Newman-Keuls 
homogeneous subset analysis (subset for α = 0.05); N.S. = not significant. 
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Online methods 
Ethical approvals 
All experiments involving the use of animals were reviewed and approved by the 
University of Edinburgh Ethical Review Committee and performed under license 
in accordance with the United Kingdom Animals (Scientific Procedures) Act 1986 
and compliant with the GlaxoSmithKline Policy on the Care, Welfare and 
Treatment of Animals. 
Generation of Kmonull mice 
Embryonic stem cells (JM8.N4, C57BL/6N background) in which the fourth 
intron of Kmo has been targeted by a ‘knockout-first’ approach were obtained 
from the International Knockout Mouse Project41 (KOMP) and microinjected into 
mouse blastocysts derived from albino C57BL/6J-Tyrc-2J mice prior to 
implantation into pseudopregnant foster dams. Litters containing chimeras were 
born which were backcrossed onto the C57BL/6J-Tyrc-2J line and offspring 
carriers of the transgene were selected on the basis of black coat colour followed 
by genotyping to be used as founders. These founders were backcrossed to 
C57BL/6J to generate a strain heterozygote (Kmotm1a(KOMP)Wtsi) for the transgene 
to establish a breeding colony. Mice were backcrossed for at least 6 generations 
and subsequently bred as heterozygous pairs to generate mice homozygous for 
the transgene (referred to as Kmonull) and wild type (Kmowt) littermate controls. 
To revert to a functional KMO biochemical phenotype, Kmonull mice were crossed 
with the Flp-deleter C57BL/6-Tg(CAG-Flpe)2Arte to excise the promoter-driven 
cassette. These mice were subsequently bred as heterozygous pairs to generate 
mice homozygous for the loxP-flanked lacZ-deleted transgene 
(Kmotm1c(KOMP)Wtsi/flox(ex5), referred to as KmoFRT-deleted), and non-transgene controls 
(Kmoflpe-wt) on the correct background strain. All mouse genotypes were 
confirmed by standard PCR-based genotyping of genomic DNA isolated from ear 
clips. The following primer sequences were used for PCR genotyping: LacZ: 5’- 
GAGTTGCGTGACTACCTACGG-3’ and 5’-GTACCACAGCGGATGGTTCGG-3’ to yield a 
single PCR product of 453 base pairs representing the targeted Kmotm1a(KOMP)Wtsi 
allele. Kmo primers: 5’-GCATTAAAGGACAGTCAACCTG-3’ and 5’-
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CACTGGACTGTGAGTGCTTG-3’ to generate an 830 base pair band representing 
the non-targeted Kmo allele, or no band representing the recombined Kmo allele. 
Kmo mRNA tissue expression 
We made cDNA using a Quantitect kit applied to RNA extracts of tissue made 
using microRNAEasy kits (Qiagen). We used inventoried TaqMan assays for 
mouse Kmo in a standard TaqMan FAST Assay with amplification detected on an 
AB7500 FAST cycler (Applied Biosystems). We performed all assays as duplex 
reactions with an endogenous 18S RNA internal control. 
LC-MS/MS analysis of tryptophan metabolites 
Samples of serum, plasma, lysate or tissue homogenate were diluted to a ratio of 
2:5 in 5 mM ammonium formate containing 0.1% trifluoracetic acid. Protein was 
precipitated by the addition of ice-cold 100% trichloroacetic acid, samples 
incubated for 30 minutes at 4 °C and centrifuged to obtain the supernatant. 
Serial dilutions of each tryptophan metabolite were prepared over appropriate 
concentration ranges to prepare a calibration curve to permit quantitation. 10µL 
volumes of each sample were injected onto a Waters XSelect HSS PFP column 
(2.5 µm; 100 × 3 mm internal diameter, Waters, Elstree, Herts., UK) using a 
Waters Acquity UPLC autosampler, coupled to an ABSciex QTRAP 5500 mass 
spectrometer. The flow rate was 0.35 mL/min at 25 °C. Separation was carried 
out using a A – water, B – methanol gradient (both containing 0.1% formic acid). 
Conditions were 50% to 60% B over 60 seconds, 65% to 35% B over 180 
seconds, hold 65% B for 110 seconds, 65% to 50% B over 10 seconds and 
requilibration at 50% B for 200 seconds. The total run time was 10 minutes. The 
mass spectrometer was operated in positive ion electrospray mode. The 
transitions for the protonated analytes were kynurenine (m/z 209-192), 3–
hydroxykynurenine (m/z 225-202), tryptophan (m/z 205-188), kynurenic acid 
(m/z 190-144), 3HAA (m/z 154-136), d5-tryptophan (m/z 210-122), d4-
kynurenine (m/z 213-150), d4-kynurenic acid (m/z 194-148), d3-3–
hydroxykynurenine(m/z 228-165) and d3-HAA(m/z 157-139). Collision energies 
were 29, 15, 11, 31, 33, 37 29, 31, 17 and 31 V respectively. Data was acquired 
and processed using Analyst 3.0 software (ABI Sciex). 
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KMO tissue activity assay 
To assay for KMO activity mouse liver tissue (100 mg) was homogenized in 1 ml 
0.32 µM sucrose solution, centrifuged and the supernatant removed. Total 
protein concentration was evaluated using the Pierce BCA kit. A final 
concentration of 200 µg/ml total protein was added to a master mix containing 
200µM kynurenine, 800µM NADP, 3 mM G-6-P, 1 unit G6PD, 4 mM MgCl2 and 2 
mM HEPES pH 7.4 and incubated for 2 h at 37 °C at 200 rpm on an orbital shaker. 
Assays were terminated by addition of 500 µl acetonitrile, 250 ng/ml d5-
tryptophan, dried down at 65 °C under nitrogen then re-solubilized in 100 µl 
70:30 water:methanol prior to LC-MS/MS analysis. Separation of 3–
hydroxykynurenine was carried out as described for the cellular KMO enzyme 
inhibition assay.  
Experimental acute pancreatitis 
To induce experimental AP in mice we adapted an existing model42. Briefly, male 
mice aged 20 ± 1 weeks (mean ± s.e.m., no age difference between experimental 
groups)  from our transgenic breeding colony (housed in groups in 12-hour light 
cycles with free access to standard chow and water) were anaesthetized with 
inhaled isoflurane induction followed by i.p. metomidate and ketamine, using s.c. 
buprenorphine analgesia to allow laparotomy and retrograde intraductal 
injection of 100 µl of 5% sodium taurocholate, followed by i.p. bolus deposition 
of caerulein (30 µg/kg in 500 µl 0.9% saline). Sham-operated control mice 
underwent anaesthesia, laparotomy and i.p. deposition of 500 µl 0.9% saline. 
Mice were recovered in a warm area and housed singly for the duration of the 
experiment. At euthanasia, mice were re-anaesthetised with isoflurane and 
rapidly exsanguinated by direct cardiac puncture prior to tissue sampling into 
10% buffered formalin or liquid nitrogen as appropriate. In exploratory 
phenotyping studies, mice were given 1 mg/kg deuterated d5-tryptophan i.v. 1 
hour before euthanasia. 
To induce experimental AP in rats, we used our variation43 of the 
combined model of AP in rats described in detail elsewhere44.  Briefly, male 
Sprague-Dawley outbred rats aged 8 to 12 weeks (Harlan Inc., UK) housed in 
groups in 12-hour light cycles were allowed free access to standard chow and 
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water and acclimated for greater than 7 days after delivery. We placed carotid 
arterial and jugular venous cannulas under general anaesthetic without recovery 
using inhaled isoflurane with oxygen and analgesia using buprenorphine s.c.. At 
laparotomy, we gave a 10-minute pressure-controlled retrograde biliopancreatic 
infusion of 10 mM glycodeoxycholic acid in glycyl-glycine buffer pH 8.0. This was 
followed by supramaximal pancreatic stimulation by a 6h infusion of caerulein 
(Sigma) at 5 µg/kg/hour. For exploratory studies of tryptophan dynamics we 
administered 1 mg/kg deuterated d5-tryptophan i.v. 1 hour before euthanasia in 
all groups of rats although this data is not reported here. As we have previously 
reported45, this model results in amylasemia, histological acute pancreatitis with 
necrosis, haemoconcentration and metabolic acidosis, with a systemic 
inflammatory response including pyrexia and tachypnoea. We retrieved tissues 
into 10% buffered formalin or liquid nitrogen as appropriate. Amylase, albumin, 
ALT, glucose, urea and creatinine were analyzed in serum extracts utilising 
commercial kits (Alpha Laboratories Ltd.  Eastleigh, UK) adapted for use on a 
Cobas Fara centrifugal analyzer (Roche Diagnostics Ltd, Welwyn Garden City, 
UK). Pancreatic edema (graded 0-3), inflammatory cell infiltrate (graded 0-3) 
and acinar cell necrosis (graded 0-3) were scored in an observer-blind fashion 
according to the system previously reported46. Mouse cytokines were analyzed 
using Mouse ProInflammatory 7-Plex Ultra-Sensitive Kit (IL-1β, IL-12p70, IFNγ, 
IL-6, KC/GRO, IL-10 and TNFα) according to the manufacturers protocols (Meso 
Scale Discovery, Gaithersburg, MD, USA). Imaging of the plate was performed 
using a Sector 2400 Imager (Meso Scale Discovery, Gaithersburg, MD, USA). A 
standard curve for each analyte was curve-fitted, allowing determination of the 
concentration in pg cytokine per ml. Rat cytokines were analyzed using a Rat 
Fluorokine MAP Base Luminex Performance Assay cytokine kit with IFNγ, IL-10, 
L-selectin/CD62L, IL-18/IL-1F4, TNF-alpha, IL-1β/IL-1F2 and IL-6 individual 
bead sets, according to the manufacturer’s protocol (R&D Systems, MN, USA). 
The level of fluorescence of the cytokine-specific beads was analyzed using Bio-
Rad Bio-Plex 200 system (BioRad, CA, USA). Cytokine concentrations were 
determined based on a standard curve included in each plate, using cytokine 
standards provided by the manufacturer. 
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Histology and digital image analysis 
Sections (3µm) of formalin-fixed paraffin embedded tissue were de-waxed and 
taken through a decreasing series of graded alcohols to water.  Haematoxylin 
and eosin staining were performed according to standard protocols. 
Haematoxylin and eosin stained pancreas and kidney sections were scored in a 
blinded fashion by a pathologist using previously published parameters46,47. We 
assayed TUNEL using a DeadEnd™ Fluorometric or Colorimetric Kits (Promega 
Inc.) according to the manufacturer’s protocol. Immunohistochemistry was done 
according to standard protocols. The following primary antibodies were used: 
anti-mouse F4/80 BM8 antibody #14-4801 (eBioscience, Hatfield, UK) at 1:100 
dilution; rabbit anti-MPO polyclonal antibody #1224 (Merck Millipore 
Corporation) at 1:1,000 dilution for both rat and mouse MPO; mouse anti-rat 
CD68 (ED-1) monoclonal antibody MCA 341R (AbD Serotec) at 1:200 dilution. 
Visualisation was with diaminobenzoate (DAB) according to standard protocols. 
Immunohistochemistry slides were scanned in their entirety using an Axio 
Scan.Z1 system (Zeiss microscopy GmbH, Oberkochen, Germany) and stored as 
.czi files before export as reduced sized .jpg files into ImageJ. 
For mouse lung and kidney TUNEL enumeration, three representative 
100× magnification fields were sampled directly using a fluorescence 
microscope Zeiss Axioskop2 with AxioCamMR3, captured with Axiovision 
software, or in a second imaging batch using a stereologer microscope Nikon 
Eclipse E800 captured with ImagePro software, then exported as .jpg or .tif files. 
No formal investigator blinding was performed. In order to allow comparison of 
images from both imaging batches, three areas equivalent to a 100× image of 
each composite tile-scanned image were sampled from the entire section and 
exported as .jpg or .tif. Images were imported into ImageJ and TUNEL positive 
cells were enumerated. For lung tissue, TUNEL positive cells were expressed per 
unit tissue area, where the tissue area was determined by applying the following 
settings in ImageJ: RGB split file, green channel, adjust threshold manually 
according to the threshold intensity histogram and screen image to include all 
tissue, then running the Measure macro in ImageJ. For kidney TUNEL analysis in 
mice, the denominator tissue area was the sampled field in 106 pixels. The 
average score of 3 fields per section was given as the score for that animal. 
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For rat lung TUNEL enumeration, the entire available area of the tile-
scanned lung section (excluding the pleural surface which was deselected 
manually) was analyzed using the cell count algorithm, applying the following 
settings: RGB split file, threshold 170/255 on green channel, circularity 0-1.0, 
size 20-10,000 pixel^2. For rat kidney sections, the entire outer medullary stripe 
available for each tiled image was selected manually and analyzed using the cell 
count algorithm. No formal investigator blinding was performed. Background 
tissue areas for the denominator were determined as described for mice. 
Enumeration of MPO+, F4/80+ and ED1+ cells was done using ImageJ and 
expressed as positive cells per million pixels. For lung and kidney tissue, counts 
were expressed per unit area of tissue. For pancreas tissue, because many 
infiltrating inflammatory cells occupy the spaces between pancreatic acinar cells 
and lobules, immunopositive cell counts are expressed per unit area of the 
measured field. For mouse F4/80 counts in lung and kidney, the ImageJ 
algorithm was not able to accurately detect the cells due to a combination of 
shape and low staining intensity. Therefore, the cells were counted manually, 
without routine observer blinding. For those tissues undergoing manual cell 
counts, areas for the denominator were possible to be automatically determined 
in ImageJ, after thresholding to detect all tissue. After any quantitative analysis 
and for publication figure presentation only, immunohistochemistry images 
were uniformly processed across the entire image using Mac OS X Preview 
>Adjust color. 
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In vitro KMO inhibition assay 
Inhibition of KMO activity was determined as previously described12. Briefly, full 
length human KMO was expressed as a GST fusion in Sf9 cells (obtained from 
EACC, catalogue number 89070101; tested for mycoplasma according to the 
ATCC Universal Mycoplasma detection protocol, catalogue number 30-1012K 
when each vial was drawn for propagation) and used as a membrane suspension. 
Reactions were run at saturating NADPH (200 µM) and around KM for 
kynurenine (10 µM) in a buffer of 50 mM Hepes (pH 7.5), 2 mM DTT, 1 mM 
EDTA, 100 µM Chaps and stopped after 2 hours by addition of TFA. Plates were 
read on a RapidFire 200 autosampler/solid-phase extraction system (Agilent 
Technologies) coupled to a Sciex API4000 triple quadrupole mass spectrometer 
(Applied Biosystems) operated in positive ion mode. Multiple reaction 
monitoring was used to detect both kynurenine and 3–hydroxykynurenine. 
Cellular KMO enzyme inhibition assay 
Full length human KMO (GenBank Accession No. NM_003679) was prepared as a 
synthetic gene (GenScript) and ligated into pcDNA5/FRT/V5-His-TOPO 
(Invitrogen). HEK293 cells (Flp-InTM-293 cells, Invitrogen) were co-transfected 
with the resulting recombinant KMO vector and pOG55 (Invitrogen) and grown 
in the presence of hygromycin to generate the stable HEK293-huKMO cell line. 
The authenticity of each stable HEK293 cell line was confirmed by STR profiling 
(Identicell, Denmark). HEK293-huKMO cells were grown in 96-well microplate in 
DMEM medium containing 1% glutamine, 1% penicillin/streptomycin and 
incubated in 5% CO2, 95% O2 at 37 °C. Serial dilutions of compound were 
prepared in 10% DMSO from a 10 mM stock solution in 100% DMSO. In a V-
bottomed microplate, GSK180 at an appropriate concentration was added in 
duplicate at up to 10 different concentrations. For low inhibition controls, 1% 
DMSO was added to the microplate and for high inhibition controls, 10 mM 6-
(3,4-dichlorophenyl)pyrimidine-4-carboxylic acid (CAS Number 1207723-55-4) 
was added. The medium from the cells was removed and a solution of Opti-MEM 
medium containing 1% glutamine, 1% penicillin/streptomycin and 200 µM L-
kynurenine was added to the compound and control wells and incubated in 5% 
CO2, 95% O2 at 37 °C for 20 hours. Following incubation, the medium was 
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transferred to a deep well block containing acetonitrile and d5-tryptophan, 
centrifuged at 4 °C to remove debris and dried under nitrogen at 65 °C for 1h 
hour. Residues were resuspended in water/methanol (70:30) prior to LC-MS/MS 
analysis. LC-MS/MS analysis was carried out on a TSQ Quantum Discovery Triple 
Quadrupole Mass Spectrometer (ThermoFisher) coupled to an Aria CTC 
Autosampler and HPLC system (ThermoFisher). Separation was carried out on 
an Allure Biphenyl column at 50 °C using a water/methanol gradient (30% to 
70% methanol over 30 s, held at 70% methanol for 60 s, then returned to 30% 
methanol over 120 s and re-equilibrated at 30% methanol for 60 s). The peak 
area ratio for 3–hydroxykynurenine/d5-tryptophan was used to determine the 
percentage inhibition. Data were fitted to the 4-parameter logistic equation 
(Y=Bottom + (Top-Bottom)/(1+10^((LogEC50-X)*HillSlope))) using GraphPad 
Prism software. 
Freshly prepared human primary hepatocytes (Biopredict, Fr) were incubated 
overnight with compounds diluted in Williams’ E basal media (Invitrogen) 
containing 10% FBS, 100 nM dexamethasone and 400 µM L-tryptophan (Sigma). 
Following incubation LC-MS/MS analysis was carried out on cell supernatant in 
order to detect and quantify metabolites. For presentation, the percentage 
inhibition was calculated using the observed increase in kynurenine, normalized 
to 100%. Data were fitted to the 4-parameter logistic equation (Y=Bottom + 
(Top-Bottom)/(1+10^((LogEC50-X)*HillSlope))) using GraphPad Prism software 
Cellular Km determination 
HEK293 cells stably transfected with either human KMO or rat Kmo were plated 
at 2 × 104 cells per well in 96-well poly-D-lysine-coated 96-well flat-bottomed 
microplates. Opti-MEM medium containing 1% glutamine, 1% 
penicillin/streptomycin and supplemented with varying concentrations of L-
kynurenine (0 – 2,000 µM) was added and the cells incubated in 5% CO2, 95% O2 
at 37 °C for between 8 and 20 hours such that turnover was less than 15% across 
all concentrations. Each concentration of L-kynurenine was added in duplicate. 
The cell supernatants were removed and analysed by LC-MS/MS to determine 
the amount of 3–hydroxykynurenine generated. The mean data for each 
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independent experiment were fitted to the Michaelis-Menten equation (Y = Vmax 
× X/(Km + X)) using GraphPad Prism software. 
Tryptophan pathway inhibition assays 
Synthetic genes for full length human kynureninase (KYNU) and kynurenine 
amino transferase types 1 and 2 (KATI and KATII) were generated and ligated 
into the vector pET24b such that C-terminal six histidine tagged proteins were 
expressed in the E. coli strain BL21(DE3)pLysS. For KATI and KATII, E. coli were 
grown to OD600=0.6 at 37 °C with shaking and induced with 0.1 mM IPTG for 4 
hours.  For KYNU, E. coli were grown in ZYP-5052 auto-induction media48 at 37 
°C for 20 hours. Cells were harvested and lysed by sonication. N-laurylsarcosine 
was added to the KATII cell lysate to final concentration of 2% v/v, and mixed by 
vortexing. Cell free extracts were prepared by ultracentrifugation. KATI, KATII 
and KYNU were affinity purified on a 1 ml HisTrap FF column using a 0-1M 
imidazole gradient over 20 column volumes. KATI and KATII were further 
purified by anion exchange on a 1 ml HiTrap Q FF column, with a 0-1M NaCl 
gradient over 20 column volumes. 
For KATI and KATII, a stopped fluorescence assay based on the method of Wong 
et al49 was developed in 96-well format, using 1 mM sodium pyruvate and 90µM 
L-kynurenine as substrates for the KATI assay and 1 mM α-ketogluturate, 40µM 
pyridoxal 5’-phosphate (PLP) and 2 mM L-kynurenine as substrates for the 
KATII assay. Assays were incubated at 37 °C for 120 and 40 minutes 
respectively, and terminated with the addition of an equal volume of 350 mM 
ZnOAc, 50 mM NaOAc pH 5.4. Fluorescence intensity at 398 nM was measured 
following excitation at 344 nM. 
Cell line authentication and mycoplasma testing 
The authenticity of the HEK293 cells (Flp-InTM-293 cells, Invitrogen) used to 
overexpress huKMO was confirmed as 100% concordant with HEK293 by STR-
profiling (ISO15189 DANAK/ILAC accredited Identicell service, Aarhus 
University Hospital, Denmark). Transfected HEK293-huKMO cells were tested for 
mycoplasma periodically. For the batch of cells used in this assay the date of 
mycoplasma testing was 04/08/11; no mycoplasma contamination was 
detected. Cells used only as hosts for protein expression (Sf9 and E. coli strain 
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BL21(DE3)pLysS) were not formally authenticated after delivery from the 
supplier. 
Crystallography 
Crystallisation of P. fluorescens KMO and preparation of the inhibitor complex 
Crystals of apo KMO were grown by hanging drop vapor diffusion at 4 °C using 1 
µL protein at 12 mg/ml (in 20 mM HEPES pH 7.0, 20 mM Na acetate, 1 mM DTT) 
mixed with 1 µL crystallization reagent (0.1 M HEPES pH 7.0, 10% glycerol, 10% 
2-propanol, 6.5% PEG 4000, 10 mM KCl) suspended over a 1 ml reservoir of the 
crystallization reagent. The newly set drops were streak seeded using a 
previously grown crystal crushed up into a few µL of reservoir solution. A crystal 
harvesting solution was prepared consisting of 1 part ethylene glycol to 4 parts 
crystallization reagent (0.1 M HEPES pH 7.0, 8% glycerol, 10% 2-propanol, 10% 
PEG 4000, 20 mM Na tartrate) to which GSK180 was added from a 50 mM stock 
solution in DMSO to give an overall concentration of 2.5 mM inhibitor and 5% 
DMSO. The harvesting solution was gradually added to the crystal drop to excess. 
After a few minutes, crystals were flash frozen in liquid nitrogen ready for data 
collection.  
X-ray data collection and crystal structure determination 
X-ray diffraction data (900 images, 0.2° oscillation range) were collected at 100 
K using a Pilatus 6M detector at the European Synchrotron Radiation Facility 
(ESRF) beam line ID23-1. The data were processed and scaled using autoPROC50, 
utilizing XDS51, AIMLESS52 and the CCP4 suite of programs53. The crystal space 
group is P21212 with unit cell dimensions a = 186.9 Å, b = 105.3 Å, c = 133.6 Å, α 
= β = γ = 90°. Data collection statistics are given in Supplementary Table 5. The 
structure was determined using the coordinates of an isomorphous unliganded 
P. fluorescens KMO model with preliminary refinement using autoBUSTER 
(BUSTER version 2.11.5. Global Phasing Ltd., Cambridge, U.K.). The ligand was 
clearly visible in the resulting Fo-Fc electron density map. Subsequent model 
building was carried out using Coot54 and structure refinement was completed 
with autoBUSTER (R = 0.157, Rfree = 0.196). The final model has been deposited 
in the Protein Data Bank under the accession code 5fn0.  
 32
Statistical analyses  
We prospectively determined group sizes based on preliminary data, by using a 
pre-specified effect size of 2 points on the log scale for serum IL-6 as observed in 
historical experiments, estimating power 1-β=0.80 and significance zα=0.05. 
Group sizes were increased to account for potential technical failures. Animals 
were allocated to experimental groups arbitrarily without formal randomization. 
There were no exclusion criteria. Investigators were not formally blinded to 
group allocation during the experiment or when assessing the outcome. We used 
the Kolmogorov-Smirnov test to compare data to the normal distribution. We 
analyzed normally distributed data using parametric two group (t-test) or 
multiple group analyses (one-way ANOVA with post-hoc Student-Newman-Keuls 
test) using SPSS v17.0.  
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